Acalabrutinib FDA approved for treatment of adult patients with pre-treated mantle cell lymphoma

Non-Sponsored Content

By: scienterrific | Last updated: 31 October 2017 | In: US FDA Onc\Haem Approvals, Uncategorised

Article Keywords

Calquence, MCL, lymphoma, FDA, AstraZeneca, AZ, acalabrutinib, Acerta Pharma

On 31 October 2017, the FDA granted accelerated approval to acalabrutinib (Calquence®, AstraZeneca under license of Acerta Pharma BV) for treatment of adult patients with mantle cell lymphoma (MCL) and pre-treated with one or more prior therapy.

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

Non-Sponsored Content